Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.

Statin strikes out in knee osteoarthritis

28 Apr 2021

In patients with symptomatic knee osteoarthritis (OA), treatment with atorvastatin falls short of reducing cartilage volume loss over 2 years as compared with placebo, according to the results of a trial.

The multicentre trial randomized 304 patients (mean age 55.7 years, 55.6 percent female) with knee OA to receive atorvastatin 40 mg orally (n=151) or matching placebo (n=153) once daily. Most of these patients (81.6 percent) completed the trial.

There was a minimal difference in the primary endpoint of annual percentage change in tibial cartilage volume (measured using magnetic resonance imaging [MRI]) over 2 years. Atorvastatin-treated patients recorded an annual decrease of 1.66 percent, while those on placebo saw a yearly decrease of 2.17 percent (difference, 0.50 percent, 95 percent confidence interval [CI], –0.17 to 1.17).

Likewise, the annual change in tibial cartilage volume was similar in the two treatment groups.

Results were the same for the prespecified secondary endpoints. There were no significant between-group differences seen in progression of cartilage defects (odds ratio [OR], 0.86, 95 percent CI, 0.52–1.41) or bone marrow lesions (OR, 1.00, 95 percent CI, 0.62–1.63), change in pain (–36.0 vs –29.5, adjusted difference, –2.7, 95 percent CI, –27.1 to 21.7), stiffness (–14.2 vs –11.8, adjusted difference, –0.2, 95 percent CI, –12.2 to 11.8), or function (–89.4 vs –87.5, adjusted difference, 0.3, 95 percent CI, –83.1 to 83.6).

Adverse events occurred with similar frequency in the atorvastatin (n=57, 37.7 percent) and placebo (n=52, 34.0 percent) groups.

The present data do not support use of atorvastatin in the treatment of knee OA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.